Clinical trials: Disease, Hodgkin
Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004169
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00101010
- Testing
- Filgrastim, Pegfilgrastim, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
- Trial name
- MATCH (NCT05354362)
- Testing
- ATG-010 and ATG-008
- Where
- 6 sites in China
- Volunteers
- 7 people
- Sponsor
- Antengene Corporation
Cognitive Decline, Mild
Predict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices
The study will recruit 100 participants aged 65+ residing in assisted living facilities. Eligible participants will undergo an initial cognitive assessment to document their baseline cognitive status using cognitive tests…
- Trial name
- 0150-24 SOR (NCT07596186)
- Where
- Israel
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Hodgkin Lymphoma
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
This is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.
- Trial name
- FIL_Tisle-HL (NCT05977673)
- Testing
- Tislelizumab
- Where
- 12 sites in Italy
- Volunteers
- 28 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphomas characterized by a primary involvement of the skin. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes.
- Conditions
- Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome
- Trial name
- CITY (NCT07213882)
- Testing
- DT-7012
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Hodgkin's Lymphoma
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
In previous studies, the investigators found that in patients with Hodgkin's lymphoma (HL) treated with ABVD (adriamycin, bleomycin, vinblastine and decarbazine) the absence of alopecia may predict for a poor response to…
- Trial name
- NCT00969462
- Testing
- Doxorubicin
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Meir Medical Center
B-cell Non-Hodgkin's Lymphoma
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.
- Trial name
- NCT05771883
- Testing
- IMM0306, Lenalidomide capsule
- Volunteers
- 102 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Diffuse Large B Cell Lymphoma, Thrombosis
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
Comparative Evaluation of Thrombotic Risk Models in DLBCL patients Objective: To assess the impact of thrombotic risk factors and compare the performance of existing predictive models (Khorana, Throly, Model IX) in Diffuse Large…
- Trial name
- PREDIC-TO (NCT06694779)
- Where
- Italy
- Volunteers
- 1,504 people
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
Acute Lymphoblastic Leukemia, B-cell Lymphoma
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of allogenic CD19-CAR-NK cells in subjects with refractory or relapsed B-cell hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT05739227
- Testing
- allogenic CD19-CAR-NK cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xuzhou Medical University
B-cell Lymphoma, Burkitt Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT).
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04491370
- Testing
- Polatuzumab vedotin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Renal Impairment
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.
- Trial name
- NCT00750620
- Testing
- YM178
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Indolent Non-Hodgkin Lymphoma
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.
- Trial name
- TEMPO (NCT04038359)
- Testing
- Duvelisib
- Where
- 28 sites in United States, Czechia and 6 more
- Volunteers
- 103 people
- Sponsor
- SecuraBio
Cardiac Toxicity, Lymphoma
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002827
- Testing
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 294 people
- Sponsor
- Children's Oncology Group
Diffuse Large B Cell Lymphoma
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT07368270
- Testing
- Anti-PD1 armored CD19 CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Mycosis Fungoides
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
This study evaluates the effectiveness - as judged by complete response - of a single four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza (Vorinostat), in a randomized 2-arm trial after a…
- Trial name
- Resimmune® (NCT02943642)
- Testing
- A-dmDT390-bisFv(UCHT1), Vorinostat
- Sponsor
- Virogen Biotechnology Inc.
Classical Hodgkin Lymphoma
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
Study Purpose: To evaluate the efficacy and safety of sintilimab in combination with AVD chemotherapy for the treatment of pediatric and adolescent patients with low-to-intermediate risk classical Hodgkin lymphoma (cHL).
- Trial name
- NCT06848569
- Testing
- Sintilimab in combination with AVD chemotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Sun Yat-sen University
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT02561273
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of Nebraska
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Bryostatin and Vincristine in B-Cell Malignancies
This phase I trial is studying the side effects and best dose of bryostatin-1 when given together with vincristine in treating patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, or multiple myeloma.
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00003166
- Testing
- bryostatin 1, vincristine sulfate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.